http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 15 Jul 2026 16:05:13 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Board+Changes/Mobia+Medical+adds+ex-Procept+BioRobotics+CEO+to+its+board/26774104.html <p>Mobia Medical, Inc. (Nasdaq: MOBI) announced the appointment of Reza Zadno, Ph.D., to its board of directors as an independent director, effective July 14, 2026. Dr. Zadno will also serve on the company's Compensation Committee.</p> <p>Dr. Zadno brings more than 35 years of medical technology experience. He most recently served as President and CEO of PROCEPT BioRobotics (Nasdaq: PRCT), a surgical robotics company, from February 2020 to September 2025, leading the company through its 2021 IPO.</p> <p>Prior to that role, he served as President and CEO of Avedro, a public ophthalmology company, from September 2016 to November 2020, before its acquisition by http://www.streetinsider.com/Board+Changes/Mobia+Medical+adds+ex-Procept+BioRobotics+CEO+to+its+board/26774104.html Wed, 15 Jul 2026 16:05:13 -0400 MOBI PRCT http://www.streetinsider.com/Board+Changes/Mobia+Medical+adds+ex-Procept+BioRobotics+CEO+to+its+board/26774104.html <p>Mobia Medical, Inc. (Nasdaq: MOBI) announced the appointment of Reza Zadno, Ph.D., to its board of directors as an independent director, effective July 14, 2026. Dr. Zadno will also serve on the company's Compensation Committee.</p> <p>Dr. Zadno brings more than 35 years of medical technology experience. He most recently served as President and CEO of PROCEPT BioRobotics (Nasdaq: PRCT), a surgical robotics company, from February 2020 to September 2025, leading the company through its 2021 IPO.</p> <p>Prior to that role, he served as President and CEO of Avedro, a public ophthalmology company, from September 2016 to November 2020, before its acquisition by http://www.streetinsider.com/Board+Changes/Mobia+Medical+adds+ex-Procept+BioRobotics+CEO+to+its+board/26774104.html Wed, 15 Jul 2026 16:05:13 -0400 MOBI PRCT http://www.streetinsider.com/Press+Releases/Mobia+Medical+Appoints+Reza+Zadno%2C+Ph.D.%2C+to+its+Board+of+Directors/26774075.html <p>AUSTIN, Texas, July 15, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced the appointment of Reza Zadno, Ph.D., to the Board as an independent director, effective July 14, 2026. Dr. Zadno will also serve as a member of the Compensation Committee.</p> <p>“We are pleased to welcome Reza to the Mobia Medical Board of Directors,” said Richard Foust, President and Chief Executive Officer of Mobia Medical. “He has built and scaled multiple public medical technology companies, and his operational perspective http://www.streetinsider.com/Press+Releases/Mobia+Medical+Appoints+Reza+Zadno%2C+Ph.D.%2C+to+its+Board+of+Directors/26774075.html Wed, 15 Jul 2026 16:05:00 -0400 MOBI PRCT http://www.streetinsider.com/Press+Releases/Mobia+Medical+Appoints+Reza+Zadno%2C+Ph.D.%2C+to+its+Board+of+Directors/26774075.html <p>AUSTIN, Texas, July 15, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced the appointment of Reza Zadno, Ph.D., to the Board as an independent director, effective July 14, 2026. Dr. Zadno will also serve as a member of the Compensation Committee.</p> <p>“We are pleased to welcome Reza to the Mobia Medical Board of Directors,” said Richard Foust, President and Chief Executive Officer of Mobia Medical. “He has built and scaled multiple public medical technology companies, and his operational perspective http://www.streetinsider.com/Press+Releases/Mobia+Medical+Appoints+Reza+Zadno%2C+Ph.D.%2C+to+its+Board+of+Directors/26774075.html Wed, 15 Jul 2026 16:05:00 -0400 MOBI PRCT http://www.streetinsider.com/Globe+Newswire/Mobia+Medical+Appoints+Reza+Zadno%2C+Ph.D.%2C+to+its+Board+of+Directors/26774075.html <p>AUSTIN, Texas, July 15, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced the appointment of Reza Zadno, Ph.D., to the Board as an independent director, effective July 14, 2026. Dr. Zadno will also serve as a member of the Compensation Committee.</p> <p>“We are pleased to welcome Reza to the Mobia Medical Board of Directors,” said Richard Foust, President and Chief Executive Officer of Mobia Medical. “He has built and scaled multiple public medical technology companies, and his operational perspective http://www.streetinsider.com/Globe+Newswire/Mobia+Medical+Appoints+Reza+Zadno%2C+Ph.D.%2C+to+its+Board+of+Directors/26774075.html Wed, 15 Jul 2026 16:05:00 -0400 MOBI PRCT http://www.streetinsider.com/Globe+Newswire/Mobia+Medical+Appoints+Reza+Zadno%2C+Ph.D.%2C+to+its+Board+of+Directors/26774075.html <p>AUSTIN, Texas, July 15, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced the appointment of Reza Zadno, Ph.D., to the Board as an independent director, effective July 14, 2026. Dr. Zadno will also serve as a member of the Compensation Committee.</p> <p>“We are pleased to welcome Reza to the Mobia Medical Board of Directors,” said Richard Foust, President and Chief Executive Officer of Mobia Medical. “He has built and scaled multiple public medical technology companies, and his operational perspective http://www.streetinsider.com/Globe+Newswire/Mobia+Medical+Appoints+Reza+Zadno%2C+Ph.D.%2C+to+its+Board+of+Directors/26774075.html Wed, 15 Jul 2026 16:05:00 -0400 MOBI PRCT http://www.streetinsider.com/Press+Releases/PROCEPT+BioRobotics%C2%AE+to+Report+Second+Quarter+2026+Financial+Results+on+August+4th%2C+2026/26768211.html <p>SAN JOSE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=ee5Gjjt4N18vkeR7BibuHSsRKfHy5i6hlttD2P-sjhedwH3DEJ-ZSCJxflabg9KfeJQpG_JRIc1A6t3RqbOHeXKwB2wdIy_O_yCRi-LxNT4wanbnH60PA2lu51b7V_tCJ1VbTEwpKhoL-E4mpz6kXEFImdh1JC8udv0SF-Y827qBoI6e4odNfay8TVP6JCgNXa_xbaMeNf74XEjxWHkqSQHC7n5Oa-BAJcp-oUrfV01omUQOADGiNn5FjkEUn-Gg0LMkOi_KxXUbc_e58C-IiStN_vJfwPkchgkcRQZcd5PaYqcyGT1cVhiPUK2tVrnKKGkNrQNphvz9IX4_BuzZEDMv-TILuLeQDyYYD7Du4RF8LwP1XZ1PJqSVXwybi81hDuNCXLNbgK-efy4xst8KPA-zbp7pRgsIz_T0oXa8ZXrflFxnK8VLVbmU4_SO9Iji1F2iMGK_5Ql2S_BtWKqzxSNpfeTPff45rVmz5p2G6nGbN0Ec5ppKbsWoeGlCnGnBWVxdWIEMEfa9d-oXqFvFxUv8jd9rFubetPhPAU9cNauJzeabkXKEhkN4V0Vr6jA8-hzZkuPiWmoaRLbJPkJ2tjWBiJQwqyQjkIe1KAAQwNvewewayksAgDFOmvgPfHQXBeqpRjHHBf0QFkvzzt441g==" rel="nofollow" target="_blank">PROCEPT BioRobotics Corporation</a> (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2026 after market close on Tuesday, August 4, 2026. The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.</p> <p align="justify">Investors interested in listening to the conference call may do so by following one of the below links:</p> <ul type="disc"><li style="text-align:justify;">Webcast link for interested listeners: <ul http://www.streetinsider.com/Press+Releases/PROCEPT+BioRobotics%C2%AE+to+Report+Second+Quarter+2026+Financial+Results+on+August+4th%2C+2026/26768211.html Tue, 14 Jul 2026 16:05:00 -0400 PRCT http://www.streetinsider.com/Globe+Newswire/PROCEPT+BioRobotics%C2%AE+to+Report+Second+Quarter+2026+Financial+Results+on+August+4th%2C+2026/26768211.html <p>SAN JOSE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=ee5Gjjt4N18vkeR7BibuHSsRKfHy5i6hlttD2P-sjhedwH3DEJ-ZSCJxflabg9KfeJQpG_JRIc1A6t3RqbOHeXKwB2wdIy_O_yCRi-LxNT4wanbnH60PA2lu51b7V_tCJ1VbTEwpKhoL-E4mpz6kXEFImdh1JC8udv0SF-Y827qBoI6e4odNfay8TVP6JCgNXa_xbaMeNf74XEjxWHkqSQHC7n5Oa-BAJcp-oUrfV01omUQOADGiNn5FjkEUn-Gg0LMkOi_KxXUbc_e58C-IiStN_vJfwPkchgkcRQZcd5PaYqcyGT1cVhiPUK2tVrnKKGkNrQNphvz9IX4_BuzZEDMv-TILuLeQDyYYD7Du4RF8LwP1XZ1PJqSVXwybi81hDuNCXLNbgK-efy4xst8KPA-zbp7pRgsIz_T0oXa8ZXrflFxnK8VLVbmU4_SO9Iji1F2iMGK_5Ql2S_BtWKqzxSNpfeTPff45rVmz5p2G6nGbN0Ec5ppKbsWoeGlCnGnBWVxdWIEMEfa9d-oXqFvFxUv8jd9rFubetPhPAU9cNauJzeabkXKEhkN4V0Vr6jA8-hzZkuPiWmoaRLbJPkJ2tjWBiJQwqyQjkIe1KAAQwNvewewayksAgDFOmvgPfHQXBeqpRjHHBf0QFkvzzt441g==" rel="nofollow" target="_blank">PROCEPT BioRobotics Corporation</a> (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2026 after market close on Tuesday, August 4, 2026. The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.</p> <p align="justify">Investors interested in listening to the conference call may do so by following one of the below links:</p> <ul type="disc"><li style="text-align:justify;">Webcast link for interested listeners: <ul http://www.streetinsider.com/Globe+Newswire/PROCEPT+BioRobotics%C2%AE+to+Report+Second+Quarter+2026+Financial+Results+on+August+4th%2C+2026/26768211.html Tue, 14 Jul 2026 16:05:00 -0400 PRCT http://www.streetinsider.com/Analyst+PT+Change/Procept+BioRobotics+Corp+%28PRCT%29+PT+Lowered+to+%2424+at+Baird/26764383.html Baird analyst David Rescott lowered the price target on Procept BioRobotics Corp (NASDAQ: PRCT) to $24.00 (from $28.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/Procept+BioRobotics+Corp+%28PRCT%29+PT+Lowered+to+%2424+at+Baird/26764383.html Tue, 14 Jul 2026 06:25:35 -0400 PRCT http://www.streetinsider.com/Analyst+Comments/Piper+Sandler%3A+%27Should+HTFL+%26+PRCT+Be+Down+Post+OPPS%3F+What+Will+It+Take+for+BSX+to+Catch+a+Bid%3F%27/26755550.html <p>Piper Sandler analyst Matt O'Brien addresses several of the most frequently asked investor questions, offering insights into the recent stock moves in HTFL and PRCT, along with his latest views on BSX.</p><p>The analyst commented: "If you have a question, chances are someone else is wondering the same thing. That’s the point of this note series from the PSC MedTech Team – to discuss questions we’ve received that we believe other investors may also have. With that in mind, today we’re addressing questions we've been getting on the recent stock moves for HTFL and PRCT, and thoughts on what to do http://www.streetinsider.com/Analyst+Comments/Piper+Sandler%3A+%27Should+HTFL+%26+PRCT+Be+Down+Post+OPPS%3F+What+Will+It+Take+for+BSX+to+Catch+a+Bid%3F%27/26755550.html Fri, 10 Jul 2026 08:59:07 -0400 BSX HTFL PRCT http://www.streetinsider.com/Analyst+Comments/Piper+Sandler%3A+%27Should+HTFL+%26+PRCT+Be+Down+Post+OPPS%3F+What+Will+It+Take+for+BSX+to+Catch+a+Bid%3F%27/26755550.html <p>Piper Sandler analyst Matt O'Brien addresses several of the most frequently asked investor questions, offering insights into the recent stock moves in HTFL and PRCT, along with his latest views on BSX.</p><p>The analyst commented: "If you have a question, chances are someone else is wondering the same thing. That’s the point of this note series from the PSC MedTech Team – to discuss questions we’ve received that we believe other investors may also have. With that in mind, today we’re addressing questions we've been getting on the recent stock moves for HTFL and PRCT, and thoughts on what to do http://www.streetinsider.com/Analyst+Comments/Piper+Sandler%3A+%27Should+HTFL+%26+PRCT+Be+Down+Post+OPPS%3F+What+Will+It+Take+for+BSX+to+Catch+a+Bid%3F%27/26755550.html Fri, 10 Jul 2026 08:59:07 -0400 BSX HTFL PRCT http://www.streetinsider.com/Analyst+Comments/Piper+Sandler%3A+%27Should+HTFL+%26+PRCT+Be+Down+Post+OPPS%3F+What+Will+It+Take+for+BSX+to+Catch+a+Bid%3F%27/26755550.html <p>Piper Sandler analyst Matt O'Brien addresses several of the most frequently asked investor questions, offering insights into the recent stock moves in HTFL and PRCT, along with his latest views on BSX.</p><p>The analyst commented: "If you have a question, chances are someone else is wondering the same thing. That’s the point of this note series from the PSC MedTech Team – to discuss questions we’ve received that we believe other investors may also have. With that in mind, today we’re addressing questions we've been getting on the recent stock moves for HTFL and PRCT, and thoughts on what to do http://www.streetinsider.com/Analyst+Comments/Piper+Sandler%3A+%27Should+HTFL+%26+PRCT+Be+Down+Post+OPPS%3F+What+Will+It+Take+for+BSX+to+Catch+a+Bid%3F%27/26755550.html Fri, 10 Jul 2026 08:59:07 -0400 BSX HTFL PRCT http://www.streetinsider.com/Analyst+PT+Change/Truist+Securities+Downgrades+Procept+BioRobotics+Corp+%28PRCT%29+to+Hold/26727418.html (Updated - July 2, 2026 4:02 PM EDT) <p>Truist Securities analyst Richard Newitter downgraded Procept BioRobotics Corp (NASDAQ: PRCT) from Buy to Hold with a price target of $25.00 (from $30.00).</p><p>The anayst commented: "We downgrade PRCT to Hold (v Buy) on lowered confidence in the company's procedure growth re-accel. prospects (key to the multiple in our view) & we reduced '26-27E rev. We had been willing to wait out sales force restructuring efforts over the next 2-3 qtrs to show benefit even against the backdrop of increasing Uro preference towards a more profitable (despite questionable efficacy) PAE procedure. The nail in http://www.streetinsider.com/Analyst+PT+Change/Truist+Securities+Downgrades+Procept+BioRobotics+Corp+%28PRCT%29+to+Hold/26727418.html Thu, 02 Jul 2026 16:02:48 -0400 PRCT http://www.streetinsider.com/Downgrades/Truist+Securities+Downgrades+Procept+BioRobotics+Corp+%28PRCT%29+to+Hold/26727418.html (Updated - July 2, 2026 4:02 PM EDT) <p>Truist Securities analyst Richard Newitter downgraded Procept BioRobotics Corp (NASDAQ: PRCT) from Buy to Hold with a price target of $25.00 (from $30.00).</p><p>The anayst commented: "We downgrade PRCT to Hold (v Buy) on lowered confidence in the company's procedure growth re-accel. prospects (key to the multiple in our view) & we reduced '26-27E rev. We had been willing to wait out sales force restructuring efforts over the next 2-3 qtrs to show benefit even against the backdrop of increasing Uro preference towards a more profitable (despite questionable efficacy) PAE procedure. The nail in http://www.streetinsider.com/Downgrades/Truist+Securities+Downgrades+Procept+BioRobotics+Corp+%28PRCT%29+to+Hold/26727418.html Thu, 02 Jul 2026 16:02:48 -0400 PRCT http://www.streetinsider.com/Analyst+Comments/Truist+Securities+Downgrades+Procept+BioRobotics+Corp+%28PRCT%29+to+Hold/26727418.html (Updated - July 2, 2026 4:02 PM EDT) <p>Truist Securities analyst Richard Newitter downgraded Procept BioRobotics Corp (NASDAQ: PRCT) from Buy to Hold with a price target of $25.00 (from $30.00).</p><p>The anayst commented: "We downgrade PRCT to Hold (v Buy) on lowered confidence in the company's procedure growth re-accel. prospects (key to the multiple in our view) & we reduced '26-27E rev. We had been willing to wait out sales force restructuring efforts over the next 2-3 qtrs to show benefit even against the backdrop of increasing Uro preference towards a more profitable (despite questionable efficacy) PAE procedure. The nail in http://www.streetinsider.com/Analyst+Comments/Truist+Securities+Downgrades+Procept+BioRobotics+Corp+%28PRCT%29+to+Hold/26727418.html Thu, 02 Jul 2026 16:02:48 -0400 PRCT http://www.streetinsider.com/New+Coverage/Evercore+ISI+Starts+Procept+BioRobotics+Corp+%28PRCT%29+at+Outperform/26681650.html (Updated - June 24, 2026 6:03 AM EDT) <p>Evercore ISI analyst Vijay Kumar initiates coverage on Procept BioRobotics Corp (NASDAQ: PRCT) with a Outperform rating and a price target of $30.00.</p><p>The analyst commented: "PRCT is in an interesting place, with ST focusing on NT transitory impacts & ignoring LT fundamentals. For stock to work in the NT, 2H utilization will be key…and over next 12 mon, a positive WATER IV trial will expand TAM to prostate cancer (PC) and aid multiple expansion. We believe PRCT’s Aquablation has the best clinical evidence in the space and causes us to initiate with an http://www.streetinsider.com/New+Coverage/Evercore+ISI+Starts+Procept+BioRobotics+Corp+%28PRCT%29+at+Outperform/26681650.html Wed, 24 Jun 2026 06:03:15 -0400 PRCT http://www.streetinsider.com/Analyst+Comments/Evercore+ISI+Starts+Procept+BioRobotics+Corp+%28PRCT%29+at+Outperform/26681650.html (Updated - June 24, 2026 6:03 AM EDT) <p>Evercore ISI analyst Vijay Kumar initiates coverage on Procept BioRobotics Corp (NASDAQ: PRCT) with a Outperform rating and a price target of $30.00.</p><p>The analyst commented: "PRCT is in an interesting place, with ST focusing on NT transitory impacts & ignoring LT fundamentals. For stock to work in the NT, 2H utilization will be key…and over next 12 mon, a positive WATER IV trial will expand TAM to prostate cancer (PC) and aid multiple expansion. We believe PRCT’s Aquablation has the best clinical evidence in the space and causes us to initiate with an http://www.streetinsider.com/Analyst+Comments/Evercore+ISI+Starts+Procept+BioRobotics+Corp+%28PRCT%29+at+Outperform/26681650.html Wed, 24 Jun 2026 06:03:15 -0400 PRCT http://www.streetinsider.com/Downgrades/Leerink+Downgrades+Procept+BioRobotics+Corp+%28PRCT%29+to+Market+Perform/26632170.html <p>Leerink analyst Mike Kratky downgraded Procept BioRobotics Corp (NASDAQ: PRCT) from Outperform to Market Perform.</p><p>The analyst comments "We are downgrading PRCT to Market Perform from Outperform and decreasing our price target to $29 from $31. With the stock approaching our prior price target, our recent discussions with MEDACorp KOLs have dampened our enthusiasm on the near-term setup for PRCT shares as competition from prostate artery embolization (PAE) gains momentum. To provide additional perspective on this topic,we are hosting a MEDACorp KOL Pulse Call this Friday, June 12th at 11:00am ET focused on commercial trends and competitive dynamics in BPH with http://www.streetinsider.com/Downgrades/Leerink+Downgrades+Procept+BioRobotics+Corp+%28PRCT%29+to+Market+Perform/26632170.html Thu, 11 Jun 2026 06:20:05 -0400 PRCT http://www.streetinsider.com/Analyst+Comments/Leerink+Downgrades+Procept+BioRobotics+Corp+%28PRCT%29+to+Market+Perform/26632170.html <p>Leerink analyst Mike Kratky downgraded Procept BioRobotics Corp (NASDAQ: PRCT) from Outperform to Market Perform.</p><p>The analyst comments "We are downgrading PRCT to Market Perform from Outperform and decreasing our price target to $29 from $31. With the stock approaching our prior price target, our recent discussions with MEDACorp KOLs have dampened our enthusiasm on the near-term setup for PRCT shares as competition from prostate artery embolization (PAE) gains momentum. To provide additional perspective on this topic,we are hosting a MEDACorp KOL Pulse Call this Friday, June 12th at 11:00am ET focused on commercial trends and competitive dynamics in BPH with http://www.streetinsider.com/Analyst+Comments/Leerink+Downgrades+Procept+BioRobotics+Corp+%28PRCT%29+to+Market+Perform/26632170.html Thu, 11 Jun 2026 06:20:05 -0400 PRCT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROCEPT+BioRobotics+Corp++For%3A+Jun+09++Filed+by%3A+Desai+Antal+Rohit/26630573.html si-local-file:///var/storage/secattach/20260610/26630573.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROCEPT+BioRobotics+Corp++For%3A+Jun+09++Filed+by%3A+Desai+Antal+Rohit/26630573.html Wed, 10 Jun 2026 16:46:00 -0400 O.14638210 PRCT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROCEPT+BioRobotics+Corp++For%3A+Jun+09++Filed+by%3A+Desai+Antal+Rohit/26630573.html si-local-file:///var/storage/secattach/20260610/26630573.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROCEPT+BioRobotics+Corp++For%3A+Jun+09++Filed+by%3A+Desai+Antal+Rohit/26630573.html Wed, 10 Jun 2026 16:46:00 -0400 O.14638210 PRCT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROCEPT+BioRobotics+Corp++For%3A+Jun+09++Filed+by%3A+Dodrill+Amy+M./26630552.html si-local-file:///var/storage/secattach/20260610/26630552.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROCEPT+BioRobotics+Corp++For%3A+Jun+09++Filed+by%3A+Dodrill+Amy+M./26630552.html Wed, 10 Jun 2026 16:45:00 -0400 O.14638210 PRCT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROCEPT+BioRobotics+Corp++For%3A+Jun+09++Filed+by%3A+Dodrill+Amy+M./26630552.html si-local-file:///var/storage/secattach/20260610/26630552.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROCEPT+BioRobotics+Corp++For%3A+Jun+09++Filed+by%3A+Dodrill+Amy+M./26630552.html Wed, 10 Jun 2026 16:45:00 -0400 O.14638210 PRCT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROCEPT+BioRobotics+Corp++For%3A+Jun+09++Filed+by%3A+Garrett+Mary/26630538.html si-local-file:///var/storage/secattach/20260610/26630538.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROCEPT+BioRobotics+Corp++For%3A+Jun+09++Filed+by%3A+Garrett+Mary/26630538.html Wed, 10 Jun 2026 16:44:00 -0400 O.14638210 PRCT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROCEPT+BioRobotics+Corp++For%3A+Jun+09++Filed+by%3A+Garrett+Mary/26630538.html si-local-file:///var/storage/secattach/20260610/26630538.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROCEPT+BioRobotics+Corp++For%3A+Jun+09++Filed+by%3A+Garrett+Mary/26630538.html Wed, 10 Jun 2026 16:44:00 -0400 O.14638210 PRCT